Academia, industry and the slow adoption of new treatments - Takeaways - MDSpire

Academia, industry and the slow adoption of new treatments

  • By

  • Pavel Klein

  • Amanda Pong

  • Matthias Koepp

  • Wolfgang Löscher

  • Josemir W Sander

  • Edward Faught

  • August 12, 2025

  • 0 min

Share

  • 1

    The separation of academia from the pharmaceutical industry has delayed access to new treatments for patients suffering from diseases.

  • 2

    Concerns over bias led to strict no-contact policies between academia and the pharmaceutical industry, impacting clinical trial participation.

  • 3

    While ethical oversight has improved, the withdrawal of academia from industry collaboration has hindered timely access to new therapies.

  • 4

    The slow adoption of new antiseizure medications like cenobamate and fenfluramine has resulted in unnecessary suffering for patients.

  • 5

    Academic physicians play a crucial role in the adoption of new treatments; their lack of engagement with industry affects medical practice.

Original Source(s)

Academia, industry and the slow adoption of new treatments

  • by Pavel Klein, Amanda Pong, Matthias Koepp, Wolfgang Löscher, Josemir W Sander, Edward Faught

  • August 12, 2025

Related Content

Electroencephalographic abnormalities and clinical phenotypes in children with autism spectrum disorder: a single center cohort study

2026 Brain and Spine Symposium Highlights Advances Across the Neurosciences

Over two days, specialists across neurology, neurosurgery and related subspecialties came together to discuss advances in stroke care, epilepsy, movement disorders, neurodegenerative disease, neuro-oncology, brain and spine surgery, interventional pain management and emerging technologies.

  • by

  • May 21, 2026

  • 1 min
A novel gain-of-function mutation (W818R) of calcium-sensing receptor in a family with autosomal dominant hypocalcemia type 1